These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33224753)

  • 21. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
    Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
    Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of lupus anticoagulant in the era of direct oral anticoagulants.
    Hoxha A; Banzato A; Ruffatti A; Pengo V
    Autoimmun Rev; 2017 Feb; 16(2):173-178. PubMed ID: 27988438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening test for direct oral anticoagulants with the dilute Russell viper venom time.
    Pratt J; Crispin P
    Eur J Haematol; 2018 Jun; 100(6):567-574. PubMed ID: 29486103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status of oral anticoagulant adherence in Japanese patients with atrial fibrillation: A claims database analysis.
    Yagi N; Suzuki S; Nagai K; Tanaka T; Nagahama T; Arita T; Otsuka T; Yamashita T
    J Cardiol; 2021 Aug; 78(2):150-156. PubMed ID: 33663881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ; Chan NC; Eikelboom JW
    Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
    Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
    Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
    Aungraheeta R; FitzGibbon L; Reilly-Stitt C; Mumford AD
    Int J Lab Hematol; 2020 Apr; 42(2):126-133. PubMed ID: 31756037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale.
    Castellucci LA; Shaw J; van der Salm K; Erkens P; Le Gal G; Petrcich W; Carrier M
    Thromb Res; 2015 Oct; 136(4):727-31. PubMed ID: 26272305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation.
    Rossi AP; Facchinetti R; Ferrari E; Nori N; Sant S; Masciocchi E; Zoico E; Fantin F; Mazzali G; Zamboni M
    J Thromb Thrombolysis; 2018 Aug; 46(2):139-144. PubMed ID: 29761426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
    Papadaki S; Tselepis AD
    Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
    Lim MS; Chapman K; Swanepoel P; Enjeti AK
    Pathology; 2016 Dec; 48(7):712-719. PubMed ID: 27780603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics.
    Testa S; Tripodi A; Legnani C; Pengo V; Abbate R; Dellanoce C; Carraro P; Salomone L; Paniccia R; Paoletti O; Poli D; Palareti G;
    Thromb Res; 2016 Jan; 137():178-183. PubMed ID: 26672898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban.
    Ibrahim F; Calmette L; Layka A; Horellou MH; Mazoyer É; Gouin-Thibault I; Flaujac C
    Ann Biol Clin (Paris); 2016 Aug; 74(4):457-64. PubMed ID: 27492699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
    Pham PN; Brown JD
    BMC Cardiovasc Disord; 2019 Mar; 19(1):64. PubMed ID: 30890131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring plasma levels of factor Xa inhibitors: how, why and when?
    Samama MM; Amiral J; Guinet C; Le Flem L; Seghatchian J
    Expert Rev Hematol; 2013 Apr; 6(2):155-64. PubMed ID: 23547865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
    Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
    Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
    Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?
    Samoš M; Bolek T; Stančiaková L; Škorňová I; Ivanková J; Kovář F; Galajda P; Kubisz P; Staško J; Mokáň M
    Diabetes Res Clin Pract; 2018 Jan; 135():172-177. PubMed ID: 29175298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversing factor Xa inhibitors - clinical utility of andexanet alfa.
    Kaatz S; Bhansali H; Gibbs J; Lavender R; Mahan CE; Paje DG
    J Blood Med; 2017; 8():141-149. PubMed ID: 28979172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.